DNA icon

Familial Focal Epilepsy with Variable Foci via the DEPDC5 Gene

Summary and Pricing

Test Method

Sequencing and CNV Detection via NextGen Sequencing using PG-Select Capture Probes
Test Code Test Copy GenesTest CPT Code Gene CPT Codes Copy CPT Codes Base Price
DEPDC5 81479 81479,81479 $990
Test Code Test Copy Genes Test CPT Code Gene CPT Codes Copy CPT Code Base Price
4387DEPDC581479 81479,81479 $990 Order Options and Pricing

Pricing Comments

Testing run on PG-select capture probes includes CNV analysis for the gene(s) on the panel but does not permit the optional add on of exome-wide CNV analysis. Any of the NGS platforms allow reflex to other clinically relevant genes, up to whole exome or whole genome sequencing depending upon the base platform selected for the initial test.

An additional 25% charge will be applied to STAT orders. STAT orders are prioritized throughout the testing process.

This test is also offered via a custom panel (click here) on our exome or genome backbone which permits the optional add on of exome-wide CNV or genome-wide SV analysis.

Turnaround Time

3 weeks on average for standard orders or 2 weeks on average for STAT orders.

Please note: Once the testing process begins, an Estimated Report Date (ERD) range will be displayed in the portal. This is the most accurate prediction of when your report will be complete and may differ from the average TAT published on our website. About 85% of our tests will be reported within or before the ERD range. We will notify you of significant delays or holds which will impact the ERD. Learn more about turnaround times here.

Targeted Testing

For ordering sequencing of targeted known variants, go to our Targeted Variants page.


Genetic Counselors


  • Eric Bend, PhD

Clinical Features and Genetics

Clinical Features

Pathogenic variants in DEPDC5 cause several epilepsy syndromes, which are characterized by focal seizures arising from discrete areas in the brain. These include: familial focal epilepsy with variable foci (FFEVF), autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), familial mesial temporal lobe epilepsies (FMTLE), autosomal dominant epilepsy with auditory features (ADEAF), and infantile spasms. FMTLE and ADEAF have been described in only a few nuclear families. It is likely that these two phenotypes are part of the FEVF spectrum and may not be distinct syndromes (Baulac et al. 1993. PubMed ID: 27683934).

FFEVF is a phenotypically heterogeneous form of epilepsy characterized by the major feature of focal seizures. Seizures can originate from different cortical regions of the brain in members of the same family. Common EEG findings include centro-temporal spikes and temporo-posterior sharp waves. Age of onset ranges from infancy to adulthood (Lal et al. 2014. PubMed ID: 24591017; Ishida et al. 2013. PubMed ID: 23542701). In a subset of patients with FFEVF, MRI reveals focal cortical dysplasia with thickening of the cortex and blurring of the grey-white junction (Scheffer et al. 2014. PubMed ID: 24585383). MRI findings within a family can be variable, with some members showing no signs of lesional epilepsy. Intellect is generally preserved, although FFEVF patients have been reported with intellectual disability, autism spectrum, or other psychiatric disorders (Dibbens et al. 2013. PubMed ID: 23542697; Scheffer et al. 2014. PubMed ID: 24585383).

ADNFLE is a partial seizure disorder characterized by seizures that occur during non-REM sleep. Seizure onset is usually between 8 and 12 years, and patients experience predominantly nocturnal seizures with hyperkinetic, tonic, or dystonic features.

A diagnosis of DEPDC5-related epilepsy can provide important prognostic information related to therapy and reproductive planning. Drug-resistant epilepsy is documented in 54-78% of patients (Picard et al. 2014. PubMed ID: 24814846; Baldassari et al. 2019. PubMed ID: 30093711). Favorable surgery outcome has been reported in 60% of individuals in one study (Baldassari et al. 2019. PubMed ID: 30093711). Finally, precision therapy targeting the mTOR pathway has been proposed; however, to date no such medications are available (Myers and Scheffer. 2017. PubMed ID: 28406046)


DEPDC5-related epilepsy—including FFEVF and ADNFLE phenotypes—is inherited in an autosomal dominant manner. Additional genes associated with related epilepsy phenotypes include NPRL2, NPRL3, SCN3A, CHRNA4, CHRNB2, CHRNA2, and KCNT1. The fraction of focal epilepsy attributed to variants in DEPDC5 depends on the epilepsy phenotype studied and ranges from 2-37% of cases (Baulac. 2016. PubMed ID: 27323939). All pathogenic variants in DEPDC5 are believed to be inactivating and include nonsense, frameshift, and missense variants as well as multi-exon copy number losses (Baldassari et al. 2019. PubMed ID: 30093711). The variants are dispersed across the length of the protein, and no clear hotspots have been identified. Based on gnomAD data, DEPDC5 is generally loss-of-function intolerant; however, this is complicated by low quality sequence data that reduces the overall pLI score (Karczewski et al. 2020. PubMed ID: 32461654).

The majority of pathogenic variants are inherited, frequently from unaffected parents. Consistent with that, the penetrance of DEPDC5-related epilepsy is incomplete (approximately 66%, Dibbens et al. 2013. PubMed ID: 23542697; Ishida et al. 2013. PubMed ID: 23542701). However, de novo mutations also contribute to disease (Dibbens et al. 2013. PubMed ID: 23542697; Carvill et al. 2015. PubMed ID: 27066554), and in one case, somatic mosaicism was documented (Baulac et al. 2015. PubMed ID: 25623524). Despite incomplete penetrance, pathogenic variants are very rare in the gnomAD database (allele count <6 and frequency << 0.03%), and some experts recommend leveraging these data to classify more variants as benign (Baldassari et al. 2019. PubMed ID: 30093711).

DEPDC5 (Dishevelled, Egl-10, and Pleckstrin domain-containing protein 5) encodes a GTPase-activating protein (GAP) that binds to NPRL2 and NPRL3 forming the GATOR1 complex. GATOR1 negatively regulates the mTOR phosphorylation pathway (Bar-Peled et al. 2013. PubMed ID: 23723238). Left unchecked, mTOR stimulates cell growth, proliferation, and apoptosis- by acting on the cell cycle, transcription, translation and autophagy (Lasarge and Danzer. 2014. PubMed ID: 24672426). DEPDC5 is not strictly required for cellular viability. However, homozygous knockout mice exhibit preweaning lethality, and conditional knockout of DEPDC5 in mouse neurons causes several phenotypes including seizures (Iffland et al. 2019. PubMed ID: 31625153).

Clinical Sensitivity - Sequencing with CNV PG-Select

The clinical sensitivity of sequencing the DEPDC5 gene will depend on the patient’s phenotype. Pathogenic DEPDC5 variants have been reported in 12-37% of families with autosomal dominant focal epilepsy (Dibbens et al. 2013. PubMed ID: 23542697; Ishida et al. 2013. PubMed ID: 23542701). DEPDC5 variants were found in 13% (4/30) of cases of ADNFLE in which no pathogenic variants in CHRNA4, CHRNA2, or CHRNB2 were found (Picard et al. 2014. PubMed ID: 24814846).

Testing Strategy

This test is performed using Next-Generation sequencing with additional Sanger sequencing as necessary.

This test provides full coverage of all coding exons of the DEPDC5 gene, plus 10 bases of flanking noncoding DNA along with other non-coding regions in which pathogenic variants have been identified at PreventionGenetics or reported elsewhere. We define coverage as ≥20X NGS reads or Sanger sequencing.

Indications for Test

Candidates for DEPDC5 sequencing include patients with symptoms of FFEVF who have a family history of focal epilepsy consistent with autosomal dominant inheritance. In addition, DEPDC5 testing should be considered in patients with drug resistant ADNFLE (Picard et al. 2014. PubMed ID: 24814846). If possible, testing for DEPDC5 variants by way of a multi-gene panel is strongly encouraged. Targeted testing is indicated for family members of patients who have a known pathogenic variant in DEPDC5.


Official Gene Symbol OMIM ID
DEPDC5 614191
Inheritance Abbreviation
Autosomal Dominant AD
Autosomal Recessive AR
X-Linked XL
Mitochondrial MT


Name Inheritance OMIM ID
Epilepsy, familial focal, with variable foci AD 604364

Related Test

Early Infantile Epileptic Encephalopathy Panel


  • Baldassari et al. 2019. PubMed ID: 30093711
  • Bar-Peled et al. 2013. PubMed ID: 23723238
  • Baulac et al. 1993. PubMed ID: 27683934
  • Baulac et al. 2015. PubMed ID: 25623524
  • Baulac. 2016. PubMed ID: 27323939
  • Carvill et al. 2015. PubMed ID: 27066554
  • Dibbens et al. 2013. PubMed ID: 23542697
  • Iffland et al. 2019. PubMed ID: 31625153
  • Ishida et al. 2013. PubMed ID: 23542701
  • Karczewski et al. 2020. PubMed ID: 32461654
  • Lal et al. 2014. PubMed ID: 24591017
  • Lasarge and Danzer. 2014. PubMed ID: 24672426
  • Myers and Scheffer. 2017. PubMed ID: 28406046
  • Picard et al. 2014. PubMed ID: 24814846
  • Scheffer et al. 2014. PubMed ID: 24585383


Ordering Options

We offer several options when ordering sequencing tests. For more information on these options, see our Ordering Instructions page. To view available options, click on the Order Options button within the test description.

myPrevent - Online Ordering

  • The test can be added to your online orders in the Summary and Pricing section.
  • Once the test has been added log in to myPrevent to fill out an online requisition form.
  • PGnome sequencing panels can be ordered via the myPrevent portal only at this time.

Requisition Form

  • A completed requisition form must accompany all specimens.
  • Billing information along with specimen and shipping instructions are within the requisition form.
  • All testing must be ordered by a qualified healthcare provider.

For Requisition Forms, visit our Forms page

If ordering a Duo or Trio test, the proband and all comparator samples are required to initiate testing. If we do not receive all required samples for the test ordered within 21 days, we will convert the order to the most effective testing strategy with the samples available. Prior authorization and/or billing in place may be impacted by a change in test code.

Specimen Types

Specimen Requirements and Shipping Details

loading Loading... ×


An error has occurred while calculating the price. Please try again or contact us for assistance.

View Ordering Instructions

1) Select Test Method (Platform)

1) Select Test Type

2) Select Additional Test Options

No Additional Test Options are available for this test.

Note: acceptable specimen types are whole blood and DNA from whole blood only.
Total Price: loading
Patient Prompt Pay Price: loading
A patient prompt pay discount is available if payment is made by the patient and received prior to the time of reporting.
Show Patient Prompt Pay Price
Copy Text to Clipboard